Tirzepatide (Mounjaro) revolutionised obesity treatment as the first dual agonist. Now retatrutide — from the same company, Eli Lilly — adds a third mechanism. Is the upgrade worth it? This article breaks down every meaningful difference using actual clinical data.
Key Takeaways
- Tirzepatide (Mounjaro) is a dual GLP-1/GIP agonist; retatrutide adds glucagon receptor agonism as a third mechanism
- Weight loss: Retatrutide achieved 24.2% (Phase 2, 48 weeks) vs tirzepatide's 22.5% (SURMOUNT-1, 72 weeks) — retatrutide produced more weight loss in less time
- The glucagon component increases energy expenditure and dramatically reduces liver fat — benefits tirzepatide doesn't offer
- Side effect profiles are similar (primarily GI), though retatrutide may cause slightly more diarrhoea
- Tirzepatide is available now in Malaysia (RM1,088–3,000/month); retatrutide won't arrive until 2029–2030
- Both are made by Eli Lilly — retatrutide is effectively Mounjaro's next-generation successor
Medical Disclaimer: Retatrutide is an investigational drug not yet approved by any regulatory authority. Tirzepatide (Mounjaro) is approved and available in Malaysia. This comparison is based on published clinical trial data and is for informational purposes only. Consult a healthcare professional for personalised medical advice.
Understanding the Mechanisms: Dual vs Triple Agonist
The fundamental difference between these two drugs is their mechanism of action. Both come from Eli Lilly, and retatrutide essentially builds on tirzepatide's foundation by adding a third receptor target.
Tirzepatide (Mounjaro): GLP-1 + GIP
Tirzepatide was the first dual incretin agonist, targeting:
- GLP-1 receptor: Reduces appetite, slows gastric emptying, improves insulin secretion
- GIP receptor: Enhances insulin sensitivity, improves fat metabolism, may amplify GLP-1 effects
This dual mechanism produced significantly better weight loss than GLP-1-only drugs like Ozempic. In the SURMOUNT-1 trial, the highest dose (15 mg) produced 22.5% mean weight loss at 72 weeks.
Retatrutide: GLP-1 + GIP + Glucagon
Retatrutide includes everything tirzepatide does, plus:
- Glucagon receptor: Increases basal energy expenditure (you burn more calories at rest), promotes lipolysis (fat breakdown), and dramatically reduces liver fat
This third mechanism fundamentally changes the drug's approach to weight loss. Where tirzepatide primarily reduces energy intake (eating less), retatrutide also increases energy output (burning more). It's the difference between closing one door and closing two.
Mechanism Comparison Table
| Feature | Tirzepatide (Mounjaro) | Retatrutide |
|---|---|---|
| GLP-1 receptor agonism | ✅ | ✅ |
| GIP receptor agonism | ✅ | ✅ |
| Glucagon receptor agonism | ❌ | ✅ |
| Appetite suppression | Strong | Strong |
| Slowed gastric emptying | Yes | Yes |
| Insulin sensitivity improvement | Yes | Yes |
| Increased energy expenditure | Minimal | Significant (glucagon) |
| Enhanced fat oxidation | Moderate | Significant (glucagon) |
| Liver fat reduction | Moderate (~40-50%) | Dramatic (~86%) |
Weight Loss Comparison: The Numbers
This is what most patients care about. Let's compare the data directly.
Cross-Trial Comparison
| Metric | Tirzepatide (SURMOUNT-1) | Retatrutide (Phase 2) |
|---|---|---|
| Trial phase | Phase 3 | Phase 2 |
| Participants | 2,539 | 338 |
| Duration | 72 weeks | 48 weeks |
| Best dose | 15 mg/week | 12 mg/week |
| Mean weight loss (best dose) | 22.5% | 24.2% |
| % losing ≥10% | 91% | 100% |
| % losing ≥15% | 78% | 93% |
| % losing ≥20% | 63% | 75% |
| Weight loss plateau reached? | Yes (~65 weeks) | No (still declining at 48 weeks) |
Critical context: Retatrutide achieved superior weight loss in a shorter timeframe. The 48-week data showed curves still declining, meaning the true maximum weight loss for retatrutide could be substantially higher than 24.2%. If Phase 3 data at 72 weeks confirms continued weight loss beyond 48 weeks, the gap between these two drugs could be larger than currently apparent.
However, Phase 2 vs Phase 3 comparisons are inherently imperfect. Phase 2 trials have smaller, more selected populations, and results sometimes moderate in larger Phase 3 studies. The TRIUMPH Phase 3 programme will provide the definitive comparison.
What's a Realistic Comparison?
If we adjust for the Phase 2-to-Phase 3 attenuation that's historically observed (roughly 5–15% reduction), a reasonable estimate for retatrutide's Phase 3 efficacy is 20–23% weight loss at 48 weeks, or potentially 22–26% at 72 weeks.
This would still make retatrutide the more effective drug, but the margin over tirzepatide might be modest (2–5 percentage points) rather than dramatic. The glucagon component's additional metabolic benefits (energy expenditure, liver fat) may be more differentiating than raw weight loss numbers.
Liver Fat Reduction: Retatrutide's Clear Advantage
One area where retatrutide appears to have a substantial and clinically meaningful advantage is liver fat reduction:
- Tirzepatide: Reduces liver fat by approximately 40–50% in available data (significant, but incomplete resolution in many patients)
- Retatrutide: Reduced liver fat by approximately 86% in Phase 2, with 93% of patients achieving normalisation (<5% liver fat)
This difference is directly attributable to the glucagon component, which promotes hepatic fat oxidation (burning fat stored in the liver). For patients with NAFLD or MASH — conditions estimated to affect 25–30% of Malaysian adults — this could be a deciding factor.
Eli Lilly is running a dedicated MASH trial (TRIUMPH-4) for retatrutide, signalling their confidence in this advantage.
Side Effect Comparison
Both drugs share a similar gastrointestinal side effect profile, which is characteristic of all GLP-1-based medications. For detailed retatrutide side effect data, see our dedicated guide.
| Side Effect | Tirzepatide 15 mg (SURMOUNT-1) | Retatrutide 12 mg (Phase 2) |
|---|---|---|
| Nausea | 24% | 25% |
| Diarrhoea | 18% | 23% |
| Vomiting | 12% | 13% |
| Constipation | 11% | 12% |
| Decreased appetite | 8% | 9% |
| Discontinuation due to AEs | ~5% | ~6% |
Key differences:
- Diarrhoea is slightly more common with retatrutide, possibly related to the glucagon component's effects on gut motility
- Modest heart rate increase (2–4 bpm) seen with retatrutide but not tirzepatide — again, likely the glucagon effect
- Overall tolerability is comparable, with similar discontinuation rates
- Both drugs use gradual dose escalation to minimise GI side effects — see our guide on managing GLP-1 side effects
Cost Comparison: Malaysia Context
For Malaysian patients, cost is often the deciding factor. Here's how pricing compares:
| Factor | Tirzepatide (Mounjaro) | Retatrutide (Projected) |
|---|---|---|
| Monthly cost (Malaysia) | RM1,088–3,000 | RM2,500–4,500 (projected) |
| Availability | Available now | 2029–2030 |
| Insurance coverage | Rarely covered for weight loss | TBD |
| Generic competition | Not until late 2030s | Not until 2040s |
| Manufacturer | Eli Lilly | Eli Lilly |
At projected pricing, retatrutide would cost roughly 50–100% more per month than Mounjaro. The question patients will face: is the additional 2–5% weight loss and metabolic benefit worth an extra RM1,000–2,000/month?
For many patients, Mounjaro will remain the better value proposition — 22% weight loss at a lower cost. Retatrutide may be most justified for patients who:
- Have plateaued on tirzepatide and need greater efficacy
- Have concurrent NAFLD/MASH requiring aggressive treatment
- Have BMI >40 and need maximum possible weight loss before considering surgery
- Can afford the premium pricing
For current pricing on available medications, see our Weight Loss Injection Prices Malaysia guide.
Administration and Convenience
Both medications are administered the same way:
- Frequency: Once weekly subcutaneous injection
- Delivery device: Pre-filled pen injector (both Eli Lilly products)
- Injection sites: Abdomen, thigh, or upper arm
- Storage: Refrigerated before first use; room temperature for limited periods after
- Dose titration: Both use gradual escalation over weeks to minimise side effects
From a convenience standpoint, there is no meaningful difference. The patient experience — weekly self-injection with a small needle — will be essentially identical.
Clinical Development Stage
This is a critical practical difference:
- Tirzepatide (Mounjaro): Fully approved by FDA (2022), EMA, and NPRA Malaysia. Available in clinics across KL, Penang, Johor Bahru, and other Malaysian cities. Extensive Phase 3 and real-world data available. Safety profile well-characterised across tens of thousands of patients.
- Retatrutide: Phase 3 clinical trials ongoing (TRIUMPH programme). No regulatory approval anywhere. Phase 2 data only (338 participants). Full safety profile not yet established. Malaysian availability estimated 2029–2030.
Tirzepatide has a 3–4 year head start in real-world clinical use. By the time retatrutide reaches Malaysian pharmacies, there will be years of post-marketing surveillance data for Mounjaro, giving physicians and patients a deep understanding of its long-term profile.
The Eli Lilly Factor
Both drugs are developed by Eli Lilly, which creates an interesting competitive dynamic. Eli Lilly won't want retatrutide to cannibalise Mounjaro sales — a drug that generates billions in annual revenue. The likely strategy:
- Mounjaro positioned as the mainstream, cost-effective option for obesity and diabetes
- Retatrutide positioned as the premium, maximum-efficacy option for severe obesity and metabolic syndrome
- Price differentiation to maintain both products' market positions
- Potential combination or sequential therapy guidelines (start with Mounjaro, escalate to retatrutide if needed)
This is similar to Novo Nordisk's strategy with Ozempic (diabetes positioning) and Wegovy (obesity positioning) — same molecule, different brands and indications.
Which Should You Choose?
The decision framework depends entirely on your situation:
Choose Tirzepatide (Mounjaro) If:
- You want to start treatment now — it's available today in Malaysia
- You prefer a drug with extensive Phase 3 and real-world data
- Cost matters — Mounjaro is more affordable and produces excellent results (22%+ weight loss)
- You're new to GLP-1 therapy — Mounjaro is an excellent first-line option
- Your primary goal is weight loss without severe comorbidities like MASH
Consider Retatrutide When Available If:
- You've plateaued on Mounjaro and need additional weight loss
- You have NAFLD/MASH and the liver fat data is compelling for your situation
- You have severe obesity (BMI >40) and want maximum pharmacological weight loss before considering surgery
- Cost is not a primary concern
- You want the most potent option available and are willing to wait for it
For Most Malaysian Patients Today
Mounjaro is the right choice right now. It's available, effective, and well-characterised. When retatrutide arrives in 2029–2030, it will offer an upgrade path for patients who need more — but the majority of patients will achieve excellent results with tirzepatide.
Ready to explore Mounjaro? See our Mounjaro Malaysia Guide for pricing, clinics, and everything you need to get started.
Frequently Asked Questions
Can I switch from Mounjaro to retatrutide?
This will likely be possible once retatrutide is approved, but the specific switching protocol hasn't been established yet. Both are Eli Lilly products targeting similar pathways, so a transition protocol will likely be developed during Phase 3 trials or post-approval.
Will retatrutide replace Mounjaro?
No — Eli Lilly will likely maintain both products for different market segments. Mounjaro as the mainstream option, retatrutide as the premium option. Similar to how Ozempic and Wegovy coexist despite sharing the same molecule.
Is the extra 2% weight loss worth it?
The raw weight loss difference may be modest (2–5%), but the additional metabolic benefits (energy expenditure, liver fat reduction) could be clinically meaningful for specific patient populations. The value depends on your individual health profile and budget.
What about side effects — is retatrutide worse?
Overall tolerability appears comparable. Retatrutide may cause slightly more diarrhoea and a modest heart rate increase (2–4 bpm) due to the glucagon component. Phase 3 data will provide a definitive comparison. See our retatrutide side effects guide for details.
What's the price difference in Malaysia?
Mounjaro currently costs RM1,088–3,000/month. Retatrutide is projected at RM2,500–4,500/month. That's roughly RM1,000–2,000 more per month for the additional efficacy and metabolic benefits.
What About Southeast Asian Patients Specifically?
Most obesity drug trials have been conducted predominantly in Western populations. For Malaysian and Southeast Asian patients, several factors deserve consideration:
Body Composition Differences
Asian populations tend to develop metabolic complications at lower BMI thresholds than Western populations. The WHO recommends lower BMI cutoffs for obesity in Asian populations (≥27.5 vs ≥30). This means:
- Even "moderate" weight loss of 15–20% may be sufficient for many Malaysian patients to achieve metabolic health
- Tirzepatide's 22% weight loss may be more than adequate for most Southeast Asian patients
- Retatrutide's additional efficacy may be most valuable for severely obese patients (BMI >35 by Asian standards)
NAFLD Prevalence in Malaysia
Non-alcoholic fatty liver disease affects an estimated 25–30% of Malaysian adults — one of the highest rates in Southeast Asia. Given retatrutide's dramatic liver fat reduction (86% vs tirzepatide's ~40-50%), this could be a particularly compelling reason for Malaysian patients with NAFLD to consider retatrutide when available.
Cost Sensitivity
Malaysia's median household income is approximately RM6,000–7,000/month. At projected pricing of RM2,500–4,500/month, retatrutide would consume a significant portion of household income for most Malaysians. Tirzepatide (RM1,088–3,000/month) is more accessible, though still expensive. Neither drug is currently covered by Malaysian public healthcare or most private insurance plans for weight management.
Eli Lilly's Presence in Malaysia
Eli Lilly has an established presence in Malaysia through Mounjaro distribution. This existing infrastructure should facilitate a relatively smooth retatrutide launch when the time comes. Malaysian patients who build relationships with Eli Lilly-affiliated clinics through Mounjaro treatment may have the earliest access to retatrutide upon launch.
The Bottom Line
Retatrutide and tirzepatide are evolutionary cousins — same company, overlapping mechanisms, similar administration. Retatrutide adds the glucagon component, which provides meaningful but incremental improvements in weight loss and dramatic improvements in liver fat reduction.
For the foreseeable future, Mounjaro remains the gold standard for most Malaysian patients seeking GLP-1-based weight management. When retatrutide arrives in 2029–2030, it will offer an upgrade path — but not a replacement. The right drug depends on your health profile, goals, comorbidities, and budget.
Start your journey today rather than waiting for a drug that's years away. The retatrutide results are exciting, but Mounjaro's results are available now.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment, supplement regimen, or making changes to your health routine. Individual results may vary, and what works for others may not work for you.